Quinupristin/dalfopristin: A review of its use in the management of serious Gram-positive infections

Drugs

Volumn 58, Issue 6, 1999, Pages 1061-1097

  Lamb, Harriet M ^a   Figgitt, David P ^a   Faulds, Diana ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adverse events; Antibacterial activity; Drug interactions; Pharmacodynamics; Pharmacokinetics; Quinupristin dalfopristin; Therapeutic use

Indexed keywords

ANTIBIOTIC AGENT; AZTREONAM; CYCLOSPORIN; CYTOCHROME P450 3A4; DALFOPRISTIN PLUS QUINUPRISTIN; ERYTHROMYCIN; MIDAZOLAM; NIFEDIPINE; TERFENADINE; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTHRALGIA; BACTERIAL INFECTION; CLINICAL TRIAL; CLOSTRIDIUM PERFRINGENS; DIARRHEA; DRUG EFFICACY; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; GRAM POSITIVE BACTERIUM; HUMAN; HYPERBILIRUBINEMIA; LEGIONELLA PNEUMOPHILA; META ANALYSIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORAXELLA CATARRHALIS; MYALGIA; MYCOPLASMA PNEUMONIAE; NAUSEA; PEPTOSTREPTOCOCCUS; PNEUMONIA; PRURITUS; RASH; REVIEW; SKIN INFECTION; STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE; VOMITING;

EID: 0033369771     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199958060-00008     Document Type: Review

References (210)

1. 1. Thal LA, Zervos MJ. Occurrence and epidemiology of resistance to virginiamycin and streptogramins. J Antimicrob Chemother 1999 Feb; 43: 171-6
2. 2. Leclercq R, Courvalin P. Streptogramins: an answer to antibiotic resistance in gram-positive bacteria. Lancet 1998 Aug 22; 352: 591-2
3. 3. Beyer D, Pepper K. The streptogramin antibiotics: update on their mechanism of action. Expert Opin Invest Drug 1998 Apr; 7: 591-9
4. 4. Aumercier M, Bouhallab S, Capmau M-L, et al. RP 59500: a proposed mechanism for its bactericidal activity. J Antimicrob Chemother 1992; 30 Suppl. A: 9-14
5. 5. Jones RN, Ballow CH, Biedenbach DJ, et al. Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada. Diagn Microbiol Infect Dis 1998 Jul; 31: 437-51
6. 6. Biedenbach DJ, Ballow C, Schentag JJ, et al. Quinupristin/dalfopristin antimicrobial activity and spectrum in North America: report from 1998 isolates in the global Smart study [abstract no. P168], J Antimicrob Chemother 1999 Jul; 44 Suppl. A: 77
7. 7. Fluit A, Jones RN, Ballow C, et al. Results from the European component of the global Smart program: activity of quinupristin/dalfopristin tested against gram-positive cocci [abstract no. P172]. J Antimicrob Chemother 1999 Jul; 44 Suppl. A. 78
8. 8. Gales AC, Sader HS, Jones RN, et al. Quinupristin/dalfopristin activity against Latin American (I.A) Gram-positive cocci: results from the global SMART surveillance study [abstract no. P205]. J Antimicrob Chemother 1999 Jul; 44 Suppl. A: 85
9. 9. Barry AL, Fuchs PC, Brown SD. Provisional interpretive criteria for quinupristin/dalfopristin susceptibility tests. J Antimicrob Chemother 1997 May; 39 Suppl. A: 87-92
10. 10. Jones RN, Low DE, Pfaller MA. Epidemiologic trends in nosocomial and community-acquired infections due to antibiotic-resistant Gram-positive bacteria: the role of streptogramins and other newer compounds. Diagn Microbiol Infect Dis 1999 Feb; 33: 101-12
11. 11. Qadri SMH, Ueno Y, Mostafa FMA. In vitro activity of quinupristin/dalfopristin, RP59500, against Gram-positive clinical isolates. Chemotherapy Basel 1997 Mar-Apr; 43: 94-9
12. 12. Schouten MA, Hoogkamp-Korstanje JAA. Comparative in-vitro activities of quinupristin-dalfopristin against Gram-positive bloodstream isolates. J Antimicrob Chemother 1997 Aug; 40: 213-9
13. 13. Shonekan D, Handwerger S, Mildvan D. Comparative in-vitro activities of RP59500 (quinupristin/dalfopristin), CL 329,998, CL 331,002, trovafloxacin, clinafloxacin, teicoplanin and vancomycin against Gram-positive bacteria. J Antimicrob Chemother 1997 Mar; 39: 405-9
14. 14. Wise R, Andrews JM, Boswell FJ, et al. The in-vitro activity of linezolid (U-100766) and tentative breakpoints. J Antimicrob Chemother 1998 Dec; 42: 721-8
15. 15. Barry AL, Fuchs PC, Brown SD. In vitro activity of an orally administered streptogramin (RPR 106,972) compared to quinupristin/dalfopristin and erythromycin. Eur J Clin Microbiol Infect Dis 1997 Feb; 16: 155-8
16. 16. Chang S-C, Fang C-T, Hsueh P-R, et al. In vitro activity of quinupristin/dalfopristin against clinical isolates of common Gram-positive bacteria in Taiwan. Diagn Microbiol Infect Dis 1999 Apr; 33: 299-303
17. 17. Jamjian C, Biedenbach DJ, Jones RN. In vitro evaluation of a novel ketolide antimicrobial agent, RU-64004. Antimicrob Agents Chemother 1997 Feb; 41: 454-9
18. 18. King A, May J, Phillips I. Comparative activity of quinupristin/dalfopristin and RPR 106972 and the effect of medium on in-vitro test results. J Antimicrob Chemother 1998 Dec; 42: 711-9
19. 19. Malathum K, Coque TM, Singh KV. In vitro activities of two ketolides, HMR 3647 and HMR 3004, against Gram-positive bacteria. Antimicrob Agents Chemother 1999 Apr; 43: 930-6
20. 20. Putnam SD, Jones RN, Johnson DM, et al. In vitro antimicrobial activity and MIC quality control guidelines of RPR 106972 (RPR 112808/RPR106950): a novel orally administered streptogramin combination. Diagn Microbiol Infect Dis 1997 Jul; 28: 139-47
21. 21. Sambatakou H, Giamarellos-Bourboulis EJ, Grecka P, et al. In-vitro activity and killing effect of quinupristin/dalfopristin (RP59500) on nosocomial Staphylococcus aureus and interactions with rifampicin and ciprofloxacin against methicillin-resistant isolates. J Antimicrob Chemother 1998 Mar; 41: 349-55
22. 22. Schmitz F-J, Verhoef J, Heinz H-P. In-vitro activities of quinupristin/dalfopristin and other anti-staphylococcal agents against methicillin-resistant strains of Staphylococcus aureus isolated over a 16-year period. J Antimicrob Chemother 1998 Jun; 41: 662-4
23. 23. Barry AL, Fuchs PC, Brown SD. Susceptibility to RPR 106,972 quinupristin/dalfopristin and erythromycin among recent clinical isolates of enterococci, staphylococci and streptococci from North American medical centres. J Antimicrob Chemother 1998 Nov; 42: 651-5
24. 24. von Eiff C, Peters G. Comparative in-vitro activities of moxifloxacin, trovafloxacin, quinupristin/dalfopristin and line-zolid against staphylococci. J Antimicrob Chemother 1999 Apr; 43: 569-73
25. 25. Inoue M, Saito A, Shimizu Y, et al. Susceptibilities of Enterococcus faecium, PRSP and MRSA to RP59500 and their correlations with those to other drugs [in Japanese]. Jpn J Antibiol 1999 Apr; 52: 302-12
26. 26. von Eiff C, Peters G. In-vitro activity of RP 59500, a new semi-synthetic injectable pristinamycin against staphylococci. Zentralbl Bakteriol 1996 Apr; 283: 497-501
27. 27. Lutfor AB, Kikuchi T, Tokue Y, et al. Comparative in vitro activity of vancomycin and other antimicrobial agents against methicillin-resistant Staphylococcus aureus and Enterococcus faecium in the Tohoku district of Japan. Chemotherapy 1998 Sep-Oct; 44: 318-23
28. 28. Mulazimoglu L, Drenning SD, Yu VL. In vitro activities of two novel oxazolidinones (U100592 and U100766), a new fluoroquinolone (trovafloxacin), and dalfopristin-quinupristin against Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob Agents Chemother 1996 Oct; 40: 2428-30
29. 29. Reinert RR, Kresken M, Mechery V, et al. In vitro activity of quinupristin/dalfopristin against erythromycin-susceptible and erythromycin-resistant Streptococcus pneumoniae. Eur J Clin Microbiol Infect Dis 1998 Sep; 17: 662-5
30. 30. Alcaide F, Carratala J, Linares J, et al. In vitro activities of eight macrolide antibiotics and RP-59500 (quinupristin-dalfopristin) against viridans group streptococci isolated from blood of neutropenic cancer patients. Antimicrob Agents Chemother 1996 Sep; 40: 2117-20
31. 31. Fuchs P, Barry A, Brown S. Provisional quality control parameters and interpretive criteria for testing susceptibility of Streptococcus pneumoniae and Haemophilus influenzae to quinupristin/dalfopristin (RP59500). Antimicrobial Testing Quality Control Group. Eur J Clin Microbiol Infect Dis 1998 Mar; 17: 197-201
32. 32. Wisplinghoff H, Reinert RR, Cornely O, et al. Molecular relationships and antimicrobial susceptibilities of viridans group streptococci isolated from blood of neutropenic cancer patients. J Clin Microbiol 1999 Jun; 37: 1876-80
33. 33. Manzor O, Pawlak J, Saravolatz L. In-vitro activity of 29 antimicrobial agents penicillin-resistant and -intermediate isolates of Streptococcus pneumoniae. J Antimicrob Chemother 1999 Jan; 43: 31-6
34. 34. Struwig MC, Botha PL, Chalkley LJ. In vitro activities of 15 antimicrobial agents against clinical isolates of South African enterococci. Antimicrob Agents Chemother 1998 Oct; 42: 2752-5
35. 35. Ristow TA, Noskin GA, Warren JR, et al. In vitro activity of RP 59500 (quinupristin/dalfopristin) and ramoplanin against vancomycin-resistant Enterococcus faecium. Microb Drug Resist 1995 Winter; 1: 335-9
36. 36. Bonilla HF, Perri MB, Kauffman CA. Comparative in vitro activity of quinupristin/dalfopristin against multidrug resistant Enterococcus faecium. Diagn Microbiol Infect Dis 1996 Jul; 25: 127-31
37. 37. Evans PA, Norden CW, Rhoads S, et al. In vitro susceptibilities of clinical isolates of vancomycin-resistant enterococci. Antimicrob Agents Chemother 1997 Jun; 41: 1406
38. 38. Hill RLR, Smith CT, Seyed-Akhavani M, et al. Bactericidal and inhibitory activity of quinupristin/dalfopristin against vancomycin-and gentamicin-resistant Enterococcus faecium. J Antimicrob Chemother 1997 May; 39 Suppl. A: 23-8
39. 39. Messick CR, Pendland SL. In vitro activity of chloramphenicol alone and in combination with vancomycin, ampicillin, or RP 59500 (quinupristin/dalfopristin) against vancomycin-resistant enterococci. Diagn Microbiol Infect Dis 1997 Nov; 29: 203-5
40. 40. Jorgensen JH, McElmeel ML. Activity of quinupristin/ dalfopristin and its components against Haemophilus influenzae. J Antimicrob Chemother 1997 May; 39 Suppl. A: 69-73
41. 41. Doern GV, Jones RN, Pfaller MA, et al. Haemophilus influenzae and Moraxella catarrhalis from patients with community-acquired respiratory tract infections: antimicrobial susceptibility patterns from the SENTRY Antimicrobial Program (United States and Canada, 1997). Antimicrob Agents Chemother 1999 Feb; 43: 385-9
42. 42. Biedenbach DJ, Barrett MS, Jones RN. Comparative antimicrobial activity and kill-curve investigations of novel ketolide antimicrobial agents (HMR 3004 and HMR 3647) tested against Haemophilus influenzae and Moraxella catarrhalis strains. Diagn Microbiol Infect Dis 1998 Jun; 31: 349-53
43. 43. Collins LA, Malanoski GJ, Eliopoulos GM, et al. In vitro activity of RP59500, an injectable streptogramin antibiotic, against vancomycin-resistant Gram-positive organisms. Antimicrob Agents Chemother 1993 Mar; 37: 598-601
44. 44. Neu HC, Chin N-X, Gu J-W. The in-vitro activity of new streptogramins, RP 59500, RP 57669 and RP 54476, alone and in combination. J Antimicrob Chemother 1992 Jul; 30 Suppl. A: 83-94
45. 45. Barry AL, Fuchs PC. In vitro activities of a streptogramin (RP59500), three macrolides, and an azalide against four respiratory tract pathogens. Antimicrob Agents Chemother 1995 Jan; 39: 238-40
46. 46. Johnson CC, Slavoski L, Schwartz M, et al. In vitro activity of RP 59500 (quinupristin/dalfopristin) against antibiotic-resistant strains of Streptococcus pneumoniae and enterococci. Diagn Microbiol Infect Dis 1995 Mar; 21: 169-73
47. 47. Andrews JM, Wise R. The in-vitro activity of a new semi-synthetic streptogramin compound, RP 59500, against staphylococci and respiratory pathogens. J Antimicrob Chemother 1994 Apr; 33: 849-53
48. 48. Nakashio S, Iwasawa H, Iino S, et al. Comparative antimicrobial activity of RP 59500 (quinupristin-dalfopristin), the first semisynthetic injectable streptogramin, against Gram-positive cocci and other recent clinical pathogens [in Japanese]. Jpn J Antibiot 1997 Oct; 50: 844-53
49. 49. Garcia R, Raad I. In vitro study of the potential role of quinupristin/dulfopristin in the treatment of catheter-related staphylococcal infections. Eur J Clin Microbiol Infect Dis 1996 Dec; 15: 933-6
50. 50. Aldridge KE, Schiro DD, Varner LM. In vitro antistaphylococcal activity and testing of RP 59500, a new streptogramin, by two methods. Antimicrob Agents Chemother 1992 Apr; 36: 854-5
51. 51. Goto S, Miyazaki S, Kaneko Y. The in-vitro activity of RP 59500 against Gram-positive cocci. J Antimicrob Chemother 1992 Jul; 30 Suppl. A: 25-8
52. 52. Pecherc JC. In-vitro activity of RP 59500, a semisynthetic streptogramin, against staphylococci and streptococci. J Antimicrob Chemother 1992 Jul; 30 Suppl. A: 15-8
53. 53. Fremaux A, Sissia G, Cohen R, et al. In-vitro antibacterial activity of RP 59500, a semisynthetic streptogramin, against Streptococcus pneumoniae. J Antimicrob Chemother 1992 Jul; 30 Suppl. A: 19-23
54. 54. Verbist L, Verhaegen J. Comparative in-vitro activity of RP 59500. J Antimicrob Chemother 1992 Jul; 30 Suppl. A: 39-44
55. 55. Hoban DJ, Weshnoweski B, Palatnick L, et al. In-vitro activity of streptogramin RP 59500 against staphylococci, including bactericidal kinetic studies. J Antimicrob Chemother 1992 Jul; 30 Suppl. A: 59-65
56. 56. Inouc M, Okamoto R, Okubo T, et al. Comparative in-vitro activity of RP 59500 against clinical bacterial isolates. J Antimicrob Chemother 1992 Jul; 30 Suppl. A: 45-51
57. 57. Fass RJ. In vitro activity of RP 59500, a semisynthetic injectable pristinamycin, against staphylococci, streptococci, and enterococci. Antimicrob Agents Chemother 1991 Mar; 35: 553-9
58. 58. Archer GL, Auger P, Doern GV, et al. RP 59500, a new streptogramin highly active against recent isolates of North American staphylococci. Diagn Microbiol Infect Dis 1993 Mar-Apr; 16: 223-6
59. 59. Soussy CJ, Acar JF, Cluzel R, et al. A collaborative study of the in-vitro sensitivity to RP 59500 of bacteria isolated in seven hospitals in France. J Antimicrob Chemother 1992 Jul; 30 Suppl. A: 53-8
60. 60. Appelbaum PC, Spangler SK, Jacobs MR. Susceptibility of 539 Gram-positive and Gram-negative anacrobes to new agents, including RP59500, biapenem, trospectomycin and piperacillin/tazobactam. J Antimicrob Chemother 1993 Aug; 32: 223-31
61. 61. Rubio MC, Goñi P, Vergara Y, et al. Susceptibility of penicillin-resistance and penicillin-susceptible Streptococcus pneumoniae to newer antimicrobials. J Chemother 1999; 11: 191-4
62. 62. Schmitz F-J, Verhoef J, Fluit AC. Prevalence of resistance to MLS antibiotics in 20 European university hospitals participating in the European SENTRY surveillance programme. J Antimicrob Chemother 1999 Jun; 43: 783-92
63. 63. Baltch AL, Smith RP, Ritz WJ, et al. Comparison of inhibitory and bactericidal activities and postantibiotic effects of LY333328 and ampicillin used singly and in combination against vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother 1998 Oct; 42: 2564-8
64. 64. Spangler SK, Jacobs MR, Appelbaum PC. Susceptibilities of penicillin-susceptible and -resistant strains of Streptococcus pneumoniae to RP 59500, vancomycin, erythromycin, PD 131628, sparfloxacin, temafloxacin, win 57273, ofloxacin, and ciprofloxacin. Antimicrob Agents Chemother 1992 Apr; 36: 856-9
65. 65. Karlowsky JA, Zhanel GG, Canadian VRE Surveillance Group, et al. Vancomycin-resistant enterococci (VRE) colonization of high-risk patients in tertiary care Canadian hospitals. Diagn Microbiol Infect Dis 1999; 35: 1-7
66. 66. Jones RN. Medium and supplement effects on the antimicrobial activity of quinupristin/dalfopristin tested by agar dilution and Etest methods. Diagn Microbiol Infect Dis 1996 Oct; 26: 99-102
67. 67. Jamjian C, Barret MS, Jones RN. Antimicrobial characteristics of quinupristin/dalfopristin (Synercid at 30:70 ratio) compared to alternative ratios for in vitro testing. Diagn Microbiol Infect Dis 1997 Apr; 27: 129-38
68. 68. Leclercq R, Nantas L, Soussy C-J, et al. Activity of RP 59500, a new parenteral semisynthetic streptogramin, against staphylococci with various mechanisms of resistance to macrolide-lincosamide-streptogramin antibiotics. J Antimicrob Chemother 1992 Jul; 30 Suppl. A: 67-75
69. 69. Bouanchaud DH. In-vitro and in-vivo synergic activity and fractional inhibitory concentration (FIC) of the components of a semisynthetic streptogramin, RP 59500. J Antimicrob Chemother 1992 Jul; 30 Suppl. A: 95-9
70. 70. Williams JD, Maskell JP, Whiley AC, et al. Comparative in-vitro activity of quinupristin/dulfopristin against Enterococcus spp. J Antimicrob Chemother 1997 May; 39 Suppl. A: 41-6
71. 71. Caron F, Gold HS, Wennersten CB, et al. Influence of erythromycin resistance, inoculum growth phase, and incubation time on assessment of the bactericidal activity of RP 59500 (quinupristin-dalfopristin) against vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother 1997 Dec; 41: 2749-53
72. 72. Bergeron M, Montay G. The pharmacokinetics of quinupristin/ dalfopristin in laboratory animals and in humans. J Antimicrob Chemother 1997 May; 39 Suppl. A: 129-38
73. 73. Jones ME, Visser MR, Klootwijk M, et al. Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin. sparfloxacin, and trovafloxacin and nonquinolones linozelid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxacin-resistant and -susceptible Staphylococcus aureus strains. Antimicrob Agents Chemother 1999 Feb; 43: 421-3
74. 74. Cohen MA, Huband MD. Activity of clinafloxacin, trovafloxacin. quinupristin /dalfopristin, and other antimicrobial agents versus Staphylococcus aureus isolates with reduced susceptibility to vancomycin. Diagn Microbiol Infect Dis 1999 Jan; 33: 43-6
75. 75. Barrett MS, Jones RN. In vitro activity of quinupristin/ dalfopristin (RP 59500) against a large collection of infrequently isolated or tested species. Diagn Microbiol Infect Dis 1996 Jul; 25: 147-9
76. 76. Schwalbe RS, McIntosh AC, Qaiyumi S, et al. In vitro activity of LY333328, an investigational glycopeptide antibiotic, against enterococci and staphylococci. Antimicrob Agents Chemother 1996 Oct; 40: 2416-9
77. 77. Barry AL, Fuchs PC, Brown SD. Antipneumococcal activities of a ketolide (HMR 3647), a streptogramin (quinupristin-dalfopristin), a macrolide (erythromycin), and a lincosamide (clindamycin). Antimicrob Agents Chemother 1998 Apr; 42: 945-6
78. 78. Aldridge KE, Ashcraft DS, Sanders CV. RP 59,500 (quinupristin/dalfopristin): a new streptogramin with potent activity against penicillin-resistant Streptococcus pneumoniae. Adv Ther 1998 May-Jun; 15: 158-64
79. 79. Tuohy M, Washington JA. Antimicrobial susceptibility of viridans group streptococci. Diagn Microbiol Infect Dis 1997 Dec; 29: 277-80
80. 80. Moore LS, Schneider B, Holloway WJ. Minimal inhibitory concentrations and minimal bactericidal concentrations of quinupristin/dalfopristin against clinical isolates of Curvnebacterium jeikeium and Listeria monocytogenes. J Antimicrob Chemother 1997 May; 39 Suppl. A: 67-8
81. 81. Soriano F, Fernández-Roblas R, Calvo R, et al. In vitro susceptibilities of aerobic and facultative non-spore-forming gram-positive bacilli to HMR 3647 (RU 66647) and 14 other antimicrobials. Antimicrob Agents Chemother 1998 May; 42: 1028-33
82. 82. Koch CL, Derby P, Abratt VR. In-vitro antibiotic susceptibility and molecular analysis of anaerobic bacteria isolated in Cape Town, South Africa. J Antimicrob Chemother 1998 Aug; 42: 245-8
83. 83. Lubbe MM, Botha PL, Chalkley LJ. Comparative activity of eighteen antimicrobial agents against anaerobic bacteria isolated in South Africa. Eur J Clin Microbiol Infect Dis 1999 Jan; 18: 46-54
84. 84. Nord CE, Lindmark A, Persson I. Susceptibility of anaerobic bacteria to the new streptogramin RP 59500 in vitro, Eur J Clin Microbiol 1989 Dec; 8: 1064-7
85. 85. Izumikawu K, Hirakata Y, Yamaguchi T, et al. In vitro activities for quinupristin-dalfopristin and the streptogramin RPR 106972 against Mycoplasma pneumoniae. Antimicrob Agents Chemother 1998 Mar; 42: 698-9
86. 86. Johnson DM, Erwin ME, Barrett MS, et al. Antimicrobial activity of ten macrolide, lincosamine and streptogramin drugs tested against Legionella species. Eur J Clin Microbiol Infect Dis 1992 Aug; 11: 751-5
87. 87. Dubois J, Joly JR. In-vitro activity of RP 59500, a new synergic antibacterial agent, against Legionella spp. J Antimicrob Chemother 1992 Jul; 30 Suppl. A: 77-81
88. 88. Ridgway GL, Salman H, Dencer C, et al. The in vitro activity of Synercid (RP 59500) and RP 106972 against Chlamydia spp., Mycoplasma spp. and Ureaplasma urealyticum [abstract no. E-158]. 37th Interseience Conference on Antimicrobial Agents and Chemotherapy: 1997 28 Sep-1 Oct: Toronto: 142
89. 89. Dever LL, Torigian CV, Barbour AG. In vitro activity of the everninomicin SCH 27899 and other newer antimicrobial agents against Borrelia burgdorferi. Antimicrob Agents Chemother 1999 Jul; 43: 1773-5
90. 90. Fantin B, Leclercq R, Garry L, et al. Influence of inducible cross-resistance to macrolides, lincosamides, and streptogramin B-type antibiotics in Enterococcus faecium on activity of quinupristin-dalfopristin in vitro and in rabbits with experimental endocarditis. Antimicrob Agents Chemother 1997 May; 41: 931-5
91. 91. Lina G, Quaglia A, Reverdy M-E, et al. Distribution of genes encoding resistance to macrolides, lincosamides, and streptogramins among staphylococci. Antimicrob Agents Chemother 1999 May; 43: 1062-6
92. 92. Werner G, Klare I, Witte W. Association between quinupristin/ dalfopristin resistance in glycopeptide-resistant Enterococcus faecium and the use of additives in animal feed. Eur J Clin Microbiol Infect Dis 1998 Jun; 17: 401-2
93. 93. Chow JW, Donabedian SM, Zervos MJ. Emergence of increased resistance to quinupristin/dalfopristin during therapy for Enterococcus faecium bacteremia. Clin Infect Dis 1997 Jan; 24: 90-1
94. 94. Millichap J, Ristow TA, Noskin GA, et al. Selection of Enterococcus faecium strains with stable and unstable resistance to the streptogramin RP 59500 using stepwise in vitro exposure. Diagn Microbiol Infect Dis 1996 May; 25: 15-20
95. 95. Aeschlimann JR, Zervos MJ, Rybak MJ. Treatment of vancomycin-resistant Enterococcus faecium with RP 59500 (quinupristin-dalfopristin) administered by intermittent or continuous infusion, alone or in combination with doxycycline, in an in vitro pharmacodynamic infection model with simulated endocardial vegetations. Antimicrob Agents Chemother 1998 Oct; 42: 2710-7
96. 96. Lutzzarrouk V, Bozdogan B, Leclercq R, et al. Influence of resistance to streptogramin A-type antibiotics on the activity of quinupristin/dalfopristin (Q/D, Synercid) in vitro and in experimental endocarditis due to Staphylococcus aureus [abstract no. B-19]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy: 1998 Sep 24-27: San Diego (CA): 50
97. 97. Fantin B, Leclercq R, Merlé Y, et al. Critical influence of resistance to streptogramin B-type antibiotics on activity of RP 59500 (quinupristin-dalfopristin) in experimental endocarditis due to Staphylococcus aureus. Antimicrob Agents Chemother 1995 Feb; 39: 400-5
98. 98. Entenza JM, Drugeon H, Glauser MP, et al. Treatment of experimental endocarditis due to erythromycin-susceptible or -resistant methicillin-resistant Stapthylococcus aureus with RP 59500. Antimicrob Agents Chemother 1995 Jul; 39: 1419-24
99. 99. Tarasi A, Dever LL, Tomasz A. Activity of quinupristin/ dalfopristin against Streptococcus pneumoniae in vitro and in vivo in the rabbit model of experimental meningitis. J Antimicrob Chemother 1997 May; 39 Suppl. A: 121-7
100. 100. Trostdorf F, Reinert RR, Schmidt H, et al. Quinupristin/ dalfopristin attenuates the inflammatory response and reduces the concentration of neuron-specific enolase in the cerebrospinal fluid of rabbits with experimental Streptococcus pneumoniae meningitis. J Antimicrob Chemother 1999 Jan; 43: 87-94
101. 101. Carbon C. Quinupristin/dalfopristin: a review of its activity in experimental animal models of infection. J Antimicrob Chemother 1997 May; 39 Suppl. A: 115-9
102. 102. Brumfitt W, Hamilton-Miller JMT, Shah S. In-vitro activity of RP 59500, a new semisynthetic streptogramin antibiotic, against Gram-positive bacteria. J Antimicrob Chemother 1992 Jul; 30 Suppl. A: 29-37
103. 103. Hershberger E, Aeschlimann JR, Moldovan T, et al. Evaluation of bactericidal activities of LY333328, vancomycin, teicoplanin, ampicillin-sulbactam, trovafloxcin, and RP59500 alone or in combination with rifampin or gentamicin against different strains of vancomycin-intermediate Staphylococcus aureus by time-kill curve methods. Antimicrob Agents Chemother 1999 Mar; 43: 717-21
104. 104. Pfeil E, Weidemann B. Pharmacodynamic of quinupristin-dalfopristin (Q-D) against MSSA and MRSA in comparison to other antibacterial agents [abstract no A-36]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy: 1998 Sep 24-27: San Diego (CA): 11
105. 105. Boswell FJ, Sunderland J, Andrews JM, et al. Time-kill kinetics of quinupristin/dalfopristin on Staphylococcus aureus with and without a raised MBC evaluated by two methods. J Antimicrob Chemother 1997 May; 39 Suppl. A: 29-32
106. 106. Rybak MJ, Houlihan HH, Mercier R-C, et al. Pharmacodynamics of RP 59500 (quinupristin-dalfopristin) administered by intermittent versus continuous infusion against Staphylococcus aureus-infected fibrin-platelet clots in an in vitro infection model. Antimicrob Agents Chemother 1997 Jun; 41: 1359-63
107. 107. Berthaud N, Desnottes J-F. In-vitro bactericidal activity of quinupristin/dalfopristin against adherent Staphylococcus aureus. J Antimicrob Chemother 1997 May; 39 Suppl. A: 99-102
108. 108. Berthaud N, Huet Y, Diallo N, et al. Antistaphylococcal activities of quinupristin/dalfopristin in vitro across platelet-fibrin matrices and in experimental endocarditis. J Antimicrob Chemother 1997 May; 39 Suppl. A: 93-8
109. 109. Hamilton-Miller JMT, Shah S. Activity of quinupristin/ dalfopristin against Staphylococcus epidermidis in biofilms: a comparison with ciprofloxacin. J Antimicrob Chemother 1997 May; 39 Suppl. A: 103-8
110. 110. Matsumura S, Simor AE. Treatment of endocarditis due to vancomycin-resistant Enterococcus faecium with quinupristin/dalfopristin, doxycycline, and rifampin: a synergistic drug combination. Clin Infect Dis 1998 Dec; 27: 1554-6
111. 111. Lorian V, Fernandes F. Synergic activity of vancomycin-quinupristin/dalfopristin combination against Enterococcus faecium. J Antimicrob Chemother 1997 May; 39 Suppl. A: 63-6
112. 112. Aeschlimann JR, Rybak MJ. Pharmacodynamic analysis of the activity of quinupristin-dalfopristin against vancomycin-resistant Enterococcus faecium with differing MBCs via time-kill-curve and postantibiotic effect methods. Antimicrob Agents Chemother 1998 Sep; 42: 2188-92
113. 113. Pankuch GA, Lichtenberger C, Jacobs MR, et al. Antipneumococcal activities of RP 59500 (quinupristin-dalfopristin), penicillin G, erythromycin, and sparfloxacin determined by MIC and rapid time-kill methodologies. Antimicrob Agents Chemother 1996 Jul; 40: 1653-6
114. 114. Pankuch GA, Jacobs MR, Appelbaum PC. Study of comparative antipneumococcal activities of penicillin G, RP 59500, erythromycin, sparfloxacin, ciprofloxacin, and vancomycin by using time-kill methodology. Antimicrob Agents Chemother 1994 Sep; 38: 2065-72
115. 115. Pankuch GA, Jacobs MR, Appelbaum PC. MIC and time-kill study of antipneumococcal activities of RPR 106972 (a new oral streptogramin), RP 59500 (quinupristin-dalfopristin), pyostacine (RP 7293), penicillin G, cefotaxime, erythromycin, and clarithromycin against 10 penicillin-susceptible and -resistant pneumococci. Antimicrob Agents Chemother 1996 Sep; 40: 2071-4
116. 116. Pankuch GA, Jacobs MR. Appelbaum PC. Postantibiotic effect and postantibiotic sub-MIC effect of quinupristin-dalfopristin against Gram-positive and -negative organisms. Antimicrob Agents Chemother 1998 Nov; 42: 3028-31
117. 117. Boswell FJ, Andrews JM, Wise R. The postantibiotic effect of RP 59500 on Staphylococcus aureus including strains with a raised MBC. J Antimicrob Chemother 1994 Jun; 33: 1219-22
118. 118. Chin NX, Neu HC. Post-antibiotic effect of the new streptogramin RP 59500. Eur J Clin Microbiol Infect Dis 1992 Jul; 11: 642-5
119. 119. Nougayrede A, Berthaud N, Bouanchaud DH. Post-antibiotic effects of RP 59500 with Staphylococcus aureus. J Antimicrob Chemother 1992 Jul; 30 Suppl. A: 101-6
120. 120. Vouillamoz J, Entenza JM, Giddey M, et al. In vitro activity of synercid (quinupristin/dalfopristin) (SYN) combined with other classes of antibiotics against vancomycin-susceptible (VS) E. faecalis and vancomycin-susceptible or -resistant (VR) E. faecium (VSEF and VREF) [abstract no. E8]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy: 1996 Sep 15-18: New Orleans (LA): 82
121. B-R [abstract no. B-76], 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sep 24-27: San Diego (CA): 67
122. 122. Vouillamoz J, Entenza JM, Barry A, et al. In vitro bactericidal antagonism of Synercid (SYN) and beta-lactams against methicillin-resistant Staphylococcus aureus (MRSA) does not predict treatment failure in experimental endocarditis (EE) [abstract no. 1016]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26-29: San Francisco (CA): 63
123. 123. Vouillamoz J, Entenza JM, Giddey M, et al. In vitro efficacy of synercid (quinupristin/dalfopristin) (SYN) combined with other classes of antibiotics against methicillin-susceptible and -resistant Staphylococcus aureus [abstract no. E7]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy: 1996 Sep 15: New Orleans (LA): 82
124. 124. Zarrouk V, Bozdogan B, Leclercq R, et al. Quinupristin-dalfopristin (Q-D) alone or in combination with rifampin (Rif) in vitro and in experimental endocarditis caused by Staphylococcus aureus harboring different phenotypes of resistance to quinupristin or dalfopristin [abstract no. 1017]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26-29: San Francisco (CA): 63
125. 125. Matsumura SO, Louie L, Louie M, et al. Synergy testing of vancomycin-resistant Enterococcus faecium (VREF) against quinupristin-dalfopristin in combination with other antimicrobials [abstract no. E-63]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sep 24-27: San Diego (CA) 186
126. 126. Dever LL, Smith SM, Dejesus D, et al. Treatment of vancomycin-resistant Enterococcus faecium infections with an investigational streptogramin antibiotic (quinupristin/dalfopristin): a report of fifteen cases. Microb Drug Resist 1996 Winter; 2: 407-13
127. 127. Landman D, Quale JM. Management of infections due to resistant enterococci: a review of therapeutic options. J Antimicrob Chemother 1997; 40: 161-70
128. 128. Dever LL, Handwerger S. Persistence of vancomycin-resistant Enterococcus faecium gastrointestinal tract colonization in antibiotic-treated mice. Microb Drug Resist Mech Epidemiol Dis 1996; 2 (4): 415-21
129. 129. Rhône-Poulenc Rorer. Impact of quinupristin/dalfopristin (RP59500) on the fecal microflora in healthy volunteers, data on file
130. 130. Lefebvre P, Rey J, Harding N, et al. Open, comparative study of the pharmacokinetics and safety of a single dose of quinupristin/dalfopristin (Q/D RP 59500, Synercid) in healthy elderly volunteers and healthy young volunteers [abstract]. 20th International Congress of Chemotherapy; 1997 Jun 29: Sydney: 42-3
131. 131. Lefebvre P, Rey J, Morganroth J, et al. Open, comparative study of the pharmacokinetics and safety of a single dose of quinupristin/dalfopristin (Q/D, RP 59500) in obese and in non-obese male subjects [abstract]. 20th International Congress of Chemotherapy; 1997 Jun 29: Sydney: 42
132. 132. Chevalier P, Rey J, Boucher E, et al. Open, comparative, study of the pharmacokinetics and safety of a single dose of quinupristin/dalfopristin (Q/D, RP 59500, Synercid) in subjects with hepatic cirrhosis and healthy volunteers |abstract|. 20th International Congress of Chemotherapy; 1997 Jun 29: Sydney: 41
133. 133. Chevalier P, Rey J, Franke H, et al. Open, comparative, study of the pharmacokinetics and safety of a single dose of quinupristin/dalfopristin (Q/D, RP 59500, Synercid) in patients with severe chronic renal failure and in healthy volunteers [abstract]. 20th International Congress of Chemotherapy; 1997 Jun 29: Sydney: 42
134. 134. Johnson CA, Taylor III CA, Zimmerman SW, et al. Pharmacokinetics of quinupristin-dalfopristin in continuous ambulatory peritoneal dialysis patients. Antimicrob Agents Chemother 1999 Jan; 43: 152-6
135. 135. Etienne SD, Montay G, Le-Liboux A, et al. A phase I, double-blind, placebo-controlled study of the tolerance and pharmacokinetic behaviour of RP 59500. J Antimicrob Chemother 1992 Jul; 30 Suppl. A: 123-31
136. 136. Bruno R, Vivier N, Baille P, et al. A population pharmacokinetic analysis of dalfopristin/ quinupristin (D/Q), a new injectable antibiotic [abstract]. Clin Pharmacol Ther 1999 Feb; 65: 163
137. 137. Chevalier P, Rey J, Rouzier-Panis R, et al. Multiple-dose pharmacokinetics and safety of quinupristin/dalfopristin (Q/D RP 59500, Synercid) in healthy volunteers [abstract and poster]. 20th International Congress of Chemotherapy; 1997 Jun 29: Sydney: 42
138. 138. Le-Liboux A, Pasquier O, Montay G. Simultaneous high-performance liquid Chromatographic determination of quinupristin, dalfopristin and their main metabolites in human plasma. J Chromatogr B Biomed Sci Appl 1998 Apr 24; 708: 161-8
139. 139. Gaillard C, van Cantfort J, Montay G, et al. Disposition of the radiolabelled streptogramin RP59500 in healthy male volunteers [abstract no. 1317]. 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 1992 Oct 11-14: Anaheim (CA): 330
140. 140. Rhône-Poulenc Rorer. Summary of product characteristics. Synercid. West Mailing, UK, 1999
141. 141. Bergeron MG, Trottier S, LePage M-C, et al. A phase I. open-label, single-dose study of blood and blister fluid pharmacokinetics of quinupristin/dalfopristin (RP59500, Synercid) [abstract]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28: Toronto: 24
142. 142. Fantin B, Leclercq R, Ottaviani M, et al. In vivo activities and penetration of the two components of the streptogramin RP 59500 in cardiac vegetations of experimental endocarditis. Antimicrob Agents Chemother 1994 Mar; 38 (3): 432-7
143. 143. Lefebvre P, Geary B, Rey J, et al. Open, comparative study of the pharmacokinetics and safety of a single dose of quinupristin/dalfopristin (RP 59500, Synercid) in healthy male and female volunteers [abstract]. 20th International Congress of Chemotherapy; 1997 Jun 29: 41. Sydney
144. 144. Mündlein E, Fritz E, Pasquier O, et al. Successful treatment of multiresistant staphylococcal infections with quinupristin/ dalfopristin (RP 59500) in patients with end-stage renal disease, after renal transplantation and hepatic failure. First results of pharmacokinetics in patients treated on an emergency protocol [abstract]. 8th International Congress on Infectious Diseases; 1998 May 15: Boston (MA): 83
145. 145. Mündlein E, von Baum H, Geiss HK, et al. Life-threatening infection with multiresistant Staphylococcus epidermidis in a patient with end-stage renal disease: cure with chloramphenicol and quinupristin/dalfopristin (RP59500). Infection 1997 Jul-Aug; 25: 252-4
146. 146. Cupo-Abbott J, Holtom P, Rho JP. Focus on quinupristin/ dalfopristin: an investigational streptogramin antibiotic for the treatment of multidrug-resistant Gram-positive infections. Formulary 1998 Sep; 33: 841-57
147. 147. Sanderink G-J, Bournique B, Stevens JC, et al. In vitro metabolism and drug-drug interactions of Synercid, a new injectable antibiotic [poster]. 12th International Symposium on Microsomes and Drug Oxidation: 1998 July 20-24: Montpellier
148. 148. Ballow C, Chevalier P, Forrest A, et al. Randomized, crossover, phase I study of the interaction between quinupristin /dalfopristin (RP 59500, Synercid) at steady state and cyclosporine in healthy volunteers [abstract]. 20th International Congress of Chemotherapy; 1997 Jun 29: Sydney: 43
149. 149. Stamatakis MK, Richards JG. Interaction between quinupristin/ dalfopristin and cyclosporine. Ann Pharmacother 1997 May; 31: 576-8
150. 150. Ballow CH, Chevalier PJ, Geary WJ, et al. Cytochrome P-450 3A4 (CYP3A4) inhibition by quinupristin/dalfopristin (Q/D): interaction with nifedipine (N) in normal volunteers [abstract and poster]. 38th Intersciencc Conference on Antimicrobial Agents and Chemotherapy; 1998 Sep 24: San Diego: 24
151. 151. Ballow C, Chevalier P, Montay G, et al. A phase I study of the effect of RP59500 on the pharmacokinetics of midazolam in healthy volunteers [abstract no. P74]. J Antimicrob Chemother 1999; 44 Suppl. A: 56
152. 152. Anwer S, Keefer MC, Evans TG. Quinupristin/dalfopristin for treatment of MRSA endocarditis refractory to conventional therapy. Infect Dis Clin Pract 1998 Nov; 7: 414-6
153. 153. Grossi PA, Marone P, Corona A, et al. Quinupristin/dalfopristin (Synercid Rm) for treatment of multidrug resistant staphylococcus bacteremia. 20th International Congress of Chemotherapy; 1997 Jun 29: Sydney: 5
154. 154. Larkin J, Busciglio L, Fontanet H, et al. Staphylococcus epidermidis endocarditis treated with RP 59500 (quinupristin/dalfopristin). Clin Infect Dis 1998 May; 26: 1239-40
155. 155. Raad I, Bompart F, Hachem R. Prospective, randomized dose-ranging open phase II pilot study of quinupristin/dalfopristin versus vancomycin in the treatment of catheter-related staphylococcal bacteremia. Eur J Clin Microbiol Infect Dis 1999; 18: 199-202
156. 156. Moellering RC, Linden PK, Reinhardt J, et al. The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium. J Antimicrob Chemother 1999; 44: 251-61
157. R (quinupristin/dalfopristin) integrated summary of efficacy. 1999 Apr
158. 158. Srinath L, Kurkimilis E, Prokocimer P, et al. Quinupristin/ dalfopristin (Synercid Rm) therapy of methicillin-resistant Staphylococcus aureus infections [abstract no. P593]. J Chemother; 1999 Jul; 44 Suppl. A: 169
159. 159. Linden PK, Moellering RC, Synercid Emergency-Use Study Group. Efficacy and safety of quinupristin/dalfopristin (RP59500, Synercid) for the treatment of vancomycin-resistant Enterococcus faecium (VREF) infections in an ongoing emergency use program [abstract]. 8th International Congress on Infectious Diseases: 1998 May 15: Boston (MA): 200
160. 160. Kostman JR, Fekete T, Woodwell J, et al. Emergence of macrolide-streptogramin resistance during therapy of Staphylococcus aureus bacteremia with quinupristin/dalfopristin (RP59500) [abstract no. 161]. Clin Infect Dis 1995 Sep; 21: 746
161. 161. Gransden WR, King A, Marossy D, et al. Quinupristin/ dalfopristin in neonatal Enterococcus faecium meningitis. Arch Dis Child 1998 May; 78: F235-236. letter
162. 162. Furlong WB, Rakowski TA. Therapy with RP 59500 (quinupristin/dalfopristin) for prosthetic valve endocarditis due to enterococci with VanA/VanB resistance patterns. Clin Infect Dis 1997 Jul; 25: 163-4
163. 163. Reyzelman AM, Van-Gils CC, Hardin TC, et al. Vancomycin-resistant enterococci osteomyelitis in the foot. A case report. J Am Podiatr Med Assoc 1997 Sep; 87: 434-7
164. 164. Lai KK. Treatment of vancomycin-resistant Enterococcus faecium infections. Arch Intern Med 1996 Dec 9-23; 156:2579-84
165. 165. Zuckermann H, Halle E, Klare I, et al. Treatment of vancomycin-resistant Enterococcus faecium infection with quinupristin/dalfopristin. Facing Bacteria 1997 May 25: 44-5
166. 166. Sahgal VS, Urban C, Mariano N, et al. Quinupristin/dalfopristin (RP 59500) therapy for vancomycin-resistant Enterococcus faecium aortic graft infection: case report. Microbial Drug Resistance 1995; 1 (3): 245-7
167. 167. Cassell J, Balakrishnan I, Samarasinghe D, et al. RP59500 (quinupristin/dalfopristin): three case reports of its use in infection due to Entorococcus faecium. J Infect 1998 May; 36: 324-7
168. 168. Blumberg EA, Mandler HD, Fuchs AE, et al. Efficacy and toxicity of Synercid (quinupristin/dalfopristin) [SYN(Q/D)] for vancomycin-resistant Enterococcus faecium (VREF) infections [abstract]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1996 Sep 15: New Orleans: 286
169. 169. Hachem R, Raad I, Husni R, et al. Quinupristin/dalfopristin (Q/D) plus minocycline (M) in the treatment of vancomycin-resistant Enterococcus faecium (VREF) infection in cancer patients [abstract]. Clin Infect Dis 1998 Oct; 27: 965
170. 170. Wood CA, Blumberg EA, Fuchs AE, et al. Quinupristin/ dalfopristin (Synercid) treatment of infections caused by vancotnycin-resistant Enterococcus faecium [abstract]. Clin Infect Dis 1998 Oct; 27: 1035
171. 171. Linden PK, Pasculle AW, McDevitt D. Effect of quinupristin/ dalfopristin on the outcome of vancomycin-resistant Enterococcus faecium bacteraemia: comparison with a control cohort. J Antimicrob Chemother 1997 May; 39 Suppl. A: 145-51
172. 172. Linden PK, Wood CA, Tang J, et al. Multivariate analysis of outcome for patients with vancomycin-resistant Enterococcus faecium (VREF) infection in the quinupristin/dalfopristin (Q/D) emergency-use program [abstract no. E-164]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy: 1998 Sep 24-27: San Diego (CA): 216
173. 173. Piper J, Furness K, Steele-Moore L, et al. Quinupristin/ dalfopristin (Syncercid) resistant vancomycin resistant Enterococcus faecium (SRVRE). 37th Interscience Conference on Antimicrobial Agents and Chemotherapy: 1997 Sep 28: Toronto: 60
174. 174. Wood CA, Blumberg EA, Fuchs AE, et al. Emergence of resistance to quinupristin/dalfopristin (Synercid) during treatment of infections caused by vancomycin-resistant Enterococcus faecium (VREF) [abstract]. Clin Infect Dis 1998 Oct; 27: 1035
175. 175. Asbel L, Fuchs A, Blumberg E, et al. Four patients with prolonged vancomycin-resistant Enterococcus faecium (VREF) bacteremia treated with quinupristin/dalfopristin (Q/D) without emergence of resistance [abstract]. Clin Infect Dis 1997 Aug; 25: 419
176. 176. Nadler H, Dowzicky M, Talbot G. Characterization of isolates associated with emerging resistance to Synercid (quinupristin/dalfopristin) during worldwide clinical program [abstract]. Clin Infect Dis 1998 Oct; 27: 929
177. 177. Wood CA, Mandler HD, Fry-Arrigby BE, et al. Resistance to quinupristin/dalfopristin encountered during treatment of infections caused by vancomycin-resistant Enterococcus faecium [abstract]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy Late 1996 Sep 15: New Orleans (LA): 10
178. 178. Linden P, Pasculle AW, McDevitt D, et al. Emergence of superinfection with Enterococcus faecalis during RP59500 treatment of vancomycin-resistant Enterococcus faecium infection [abstract). 36th Interscience Conference on Antimicrobial Agents and Chemotherapy: 1996 Sep 15: New Orleans (LA): 286
179. 179. Chow JW, Davidson A, Sanford III E, et al. Superinfection with Enterococcus faecalis during quinupristin/dalfopristin therapy. Clin Infect Dis 1997 Jan; 24: 91-2
180. 180. Nadler H, Dowzicky M, Talbot G. Low rates of emerging resistance and superinfection in Synercid treated patients during worldwide clinical program [abstract]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy: 1997 Sep 28: Toronto: 19
181. 181. Moses J, Brown E, Lynn W, et al. Treatment of vancomycinresistant Enterococcus faecium CAPD-associated peritonitis with intraperitoneal administration of quinupristin/ dalfopristin [abstract]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy: 1998 24-27 Sep: San Diego (CA): 603
182. 182. Lynn WA, Clutterbuck E, Want S, et al. Treatment of CAPD-peritonitis due to glycopeptide-resistant Enterococcus faecium with quinupristin/dalfopristin [letter]. Lancet 1994 Oct 8; 344: 1025-6
183. 183. Tush GM, Huneycutt S, Phillips A, et al. Intraventricular quinupristin/dalfopristin for the treatment of vancomycin-resistant Enterococcus faecium shunt infection. Clin Infect Dis 1998 Jun; 26: 1460-1
184. 184. Nachman SA, Verma R, Egnor M. Vancomycin-resistant Enterococcus faecium shunt infection in an infant: an antibiotic cure. Microbial Drug Resistance 1995; 1 (1): 95-6
185. 185. Nachman SA, Phillips A, Gray SL. Treatment of vancomycin-resistant Enterococcus faecium central nervous system infection with intrathecal administration of quinupristin/dalfopristin [abstract]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy: 1998 24-27 Sep: San Diego (CA): 217
186. 186. Nichols RL, Graham DR, Barriere SL, et al. Treatment of hospitalized patients with complicated Gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. J Antimicrob Chemother 1999; 44: 263-73
187. 187. Fagon J-Y, Patrick H, Haas DW, et al. Treatment of gram-positive nosocomial pneumonia: prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Am J Respir Crit Care Med 2000 Jan: 161. In press
188. 188. Rehm SJ, Schmitt SK, Gordon SM, et al. Experience with quinupristin/dalfopristin (RP595000, Synercid) administration outside the hospital [abstract]. 8th International Congress of Infectious Diseases: 1998 May 15: Boston (MA): 134
189. 189. Miedzinski L, Larratt L, Rennie R, et al. Diphtheroid central line infection successfully treated with quinupristin/dalfopristin. Can J Infect Dis 1997 Nov-Dec; 8: 305
190. 190. Souweine B, Mathevon T, Bret L, et al. Successful treatment of infection due to Mycoplasma hominis with streptogramins in a renal transplant patient: case report and review. Clin Infect Dis 1998 May; 26: 1233-4
191. 191. Baughman R, US Synercid CAP Study Group. Randomized, double blind, comparative, multicenter study of quinupristin/ dalfopristin (Q/D, RP595OO, Synercid) versus combination of ceftriaxone and erythromycin in the treatment of acute community-acquired bacterial pneumonia [abstract no. 2321]. 20th International Congress of Chemotherapy; 1997 Jun-3 Jul 29: Sydney: 45-6
192. R (quinupristin/dalfopristin): expert report on clinical documentation. 15 Sep 1997
193. 193. Talbot GH, Zhu GR. Characterization of arthralgias/myalgias associated with quinupristin/dalfopristin (Synercid) [abstract]. Clin Infect Dis 1998 Oct; 27: 965
194. R (quinupristin/dalfopristin): integrated summary of safety. 14 Jul 1997
195. 195. Rhône-Poulenc Rorer Pharmaceuticals Inc. Prescribing information. Synercid I.V (quinupristin and dalfopristin for injection). Collegeville (PA), USA, 1999
196. 196. Bompart F, Dorr M, Bekele T, et al. Overview of the safety and tolerability of quinupristin/dalfopristin (Synercid, RP59500) in the global development program [abstract no. 2318]. 20th International Congress of Chemotherapy; 1997 Jun 29: Sydney: 44-5
197. 197. Linden P, Talbot G, Bompart F. Liver histopathology in liver transplant recipients with hyperbilirubinemia during quinupristin/dalfopristin therapy [poster]. 4th International Conference in the Macrolides, Azalides, Streptogramins and Ketolides; 1998 Jan 21-23: Barcelona
198. 198. Launay O, Chemlal K, Andrieu V, et al. Severe reversible reticulocytopenic anemia associated with quinupristin/dalfopristin RP59500 therapy. Clin Infect Dis 1997 Jul; 25: 156
199. 199. Pfaller MA, Jones RN, Doern GV, et al. Survey of blood stream infections attributable to Gram-positive cocci: frequency of occurrence and antimicrobial susceptibility of isolates collected in 1997 in the United States, Canada, and Latin America from the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis 1999 Apr; 33: 283-97
200. 200. Spencer RC. Predominant pathogens found in the European Prevalence of Infection in Intensive Care study. Eur J Clin Microbiol Infect Dis 1996; 15 (4): 281-5
201. 201. Fluckiger U, Widmer AF. Epidemiology of methicillin-resistant Staphylococcus aureus. Chemotherapy 1999; 45. 121-134
202. 202. Leclercq R, Courvalin P. Resistance to glycopeptides in enterococci. Clin Infect Dis 1997 Apr; 24: 545-56
203. 203. Hiramatsu K. The emergence of Staphylococcus aureus with reduced susceptibility to vancomycin in Japan. Am J Med 1998; 104 Suppl. 5A: 7-1O
204. 204. Smith TL, Pearson ML, Wilcox KR, et al. Emergence of vancomycin resistance in Staphylococcus aureus. N Engl J Med 1999 Feb 18; 340: 493-501
205. 205. van den Bogaard AE, Stobberingh EE. Antibiotic usage in animals: impact on bacterial resistance and public health. Drugs 1999 Oct; 58 (4): 589-607
206. 206. Woodford N, Palepou M-F, Johnson AP, et al. Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci [letter]. Lancet 1997 Sep 6; 350: 738
207. 207. Levy SB. Multidrug resistance: a sign of the times. N Engl J Med 1998 May 7; 338 (19): 1376-8
208. 208. Michel M, Gutmann L. Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: therapeutic realities and possibilities. Lancet 1997; 349: 1901-6
209. 209. Linden PK, Miller CB. Vancomycin-resistant enterococci: the clinical effect of a common nosocomial pathogen. Diagn Microbiol Infect Dis 1999; 33: 113-20
210. 210. Hospital Infection Control Practices Advisory Committee. Recommendations for preventing the spread of vancomycin resistance: recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). Am J Infect Control 1995 Apr; 23: 87-94